| Literature DB >> 29569388 |
Takeshi Nabe1, Masaya Matsuda1, Tomoki Ishida1, Nau Tsujimoto1, Hitomi Kido2, Haruna Kanaya1, Hiromu Takahashi1, Naoki Takemoto1, Miku Nomura1, Keiichi Ishihara3, Satoshi Akiba3, Nobuaki Mizutani4.
Abstract
Although interleukin (IL)-33 is a candidate for the aggravation of asthma, the mechanisms underlying antigen-specific IL-33 production in the lung are unclear. Therefore, we analysed the mechanisms in mice. Intra-tracheal administration of ovalbumin (OVA) evoked increases in IL-33 and IL-33 mRNA in the lungs of both non-sensitized and OVA-sensitized mice, and the increases in the sensitized mice were significantly higher than in the non-sensitized mice. However, intra-tracheal administration of bovine serum albumin did not increase the IL-33 level in the OVA-sensitized mice. Depletion of neither mast cells/basophils nor CD4+ cells abolished the OVA-induced IL-33 production in sensitized mice, suggesting that the antigen recognition leading to the IL-33 production was not related with either antigen-specific IgE-bearing mast cells/basophils or memory CD4+ Th2 cells. When a fluorogenic substrate-labelled OVA (DQ-OVA) was intra-tracheally administered, the lung cells of sensitized mice incorporated more DQ-OVA than those of non-sensitized mice. The lung cells incorporating DQ-OVA included B-cells and alveolar macrophages. The allergic IL-33 production was significantly reduced by treatment with anti-FcγRII/III mAb. Depletion of alveolar macrophages by clodronate liposomes significantly suppressed the allergic IL-33 production, whereas depletion of B-cells by anti-CD20 mAb did not. These results suggest that the administered OVA in the lung bound antigen-specific IgG Ab, and then alveolar macrophages incorporated the immune complex through FcγRII/III on the cell surface, resulting in IL-33 production in sensitized mice. The mechanisms underlying the antigen-specific IL-33 production may aid in development of new pharmacotherapies.Entities:
Keywords: B-cells; IgG; airway inflammation; interleukin-33; macrophages
Mesh:
Substances:
Year: 2018 PMID: 29569388 PMCID: PMC6099176 DOI: 10.1111/imm.12931
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.397